Dr Thomas Hutson comments on the TiNivo-2 trial and discusses upcoming and novel therapies for patients with renal cell carcinoma.
Thomas Hutson, DO, PharmD
Advertisement
Articles by Thomas Hutson, DO, PharmD
Dr Thomas Hutson shares his experience with tivozanib in his practice and ways to counsel patients regarding treatment options in the third-line setting.
Dr Thomas Hutson reviews the adverse event profile of tivozanib and provides advice to community oncologists on how to best manage these toxicities.
Dr Thomas Hutson reviews the TIVO-3 trial, including the most recent data that was presented at ASCO GU.
An overview of the treatment options available for patients with renal cell carcinoma (RCC).
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
SUNRiSE-1 Participant Shares Insights on Bladder Cancer Education
2
Fertility Preservation During Breast Cancer: ‘I Would Do It All Again’
3
Peritoneal Mesothelioma Survivor Shares Ongoing Reality of Survivorship
4
Becoming Cancer-Aware: How My Diagnosis Changed the Way My Family Sees Everyday Products
5
